Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series
- 12 Pharmacy, Royal Brompton Hospital, London, UK
- 2Ochsner MD Anderson Cancer Center, New Orleans, LA, USA
Related
- Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma
- 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
- Immune Checkpoint Inhibitor Data in Metastatic Melanoma with Pre-Existing Autoimmune Disease: A Real World Experience
- Absence of Viable Tumor Cells in Macroscopically Pigmented Regional Lymph Nodes after Immune Checkpoint Inhibitor Therapy in Duodenal Metastasis of Cutaneous Melanoma: A Case Report.
- Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression
BibTeX
@article{khan2026jak1,
title = {{147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series}},
author = {Khola Khan and Daniel H Johnson},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.0147},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.0147},
note = {CC BY},
}
RIS
TY - JOUR
TI - 147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series
AU - Khola Khan
AU - Daniel H Johnson
PY - 2026
DA - 2026/11/08
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.0147
UR - https://doi.org/10.1136/jitc-2026-sitc2026.0147
SN - 2051-1426
ER -